02 August 2021

Scientists develop a novel noninvasive MRI methodology that may allow unprecedented level of stroke lesion analysis

Sirens whining, an ambulance brings a 65-year-old woman on a stretcher to a hospital ER. She is conscious, but her mouth is drooping to one side, and she is confused and speaking unintelligibly. These telltale symptoms have allowed a preliminary diagnosis on the way to the hospital: acute ischemic stroke; a blood clot has blocked proper blood flow inside her brain.
 

01 July 2021

If you think you’re not even a tiny bit racist... think again

People are not born racist. But as children grow up, their brains, which are association-generating machines, detect and unconsciously learn, through social interactions, to associate different groups of people to different attributes, which can be positive, neutral – or negative. And when these attributes concern ethnic minorities, negative associations give rise to racial stereotypes and racism. 

24 May 2021

The reality of living with Treatment Resistant Depression

Around 15% of people will, at some point in their lives, experience Major Depressive Disorder (MDD), for which there are several treatment paths. However, it is conservatively estimated that 20% of patients experiencing MDD will not respond well to treatment. To put this in real terms, at least 1-in-66 people will experience a depressive episode that is not responsive to at least two different available forms of treatment, and thus classified as having Treatment Resistant Depression (TRD).

06 May 2021

Henrique Veiga-Fernandes, scientist at the Champalimaud Foundation, is Ambassador for Science Magazine

Henrique Veiga-Fernandes, Immunologist, Principal Investigator and one of the Directors of Champalimaud Research; and Ana Paula Pêgo, group leader at i3S - Institute for Research and Innovation in Health, now join an elite group of world-renowned scientists on the Science Review Editors Council.

29 April 2021

Champalimaud Foundation team distinguished with honourable mention by the Prémio BIAL de Medicina Clínica 2020

On the Honourable Mentions, the jury president, anatomopathology doctor and researcher Manuel Sobrinho Simões, referenced that “the jury distinguished (…) two works that show medical research's relevance and urgency; on the one hand cancer and new therapies that mark the research that is being done in this field and, on the other, the pandemic that dominated the year 2020.”

20 April 2021

Sexual receptivity and rejection may be orchestrated by the same brain region

In many species, including humans and mice, the fluctuating levels of the hormones progesterone and estrogen determine whether the female is fertile or not. And in the case of mice, whether she’s sexually receptive or not. 

The change in receptivity is striking. Female mice shift from accepting sexual partners to aggressively rejecting them across a cycle of six short days. How can the female reproductive hormones bring about such a radical behavioural change?

05 April 2021

Champalimaud Foundation takes part in the initiative "Conversas com Cientistas - Décadas de Ciência para Dias de Vacinas"

One year after the COVID-19 pandemic started in Portugal, the campaign "Conversas com Cientistas - Décadas de Ciência para Dias de Vacinas" kicks off.

01 April 2021

Imaging prior to surgery may reduce the risk of incontinence after prostate cancer removal

Radical surgical removal of the prostate is the most frequent treatment for prostate cancer when the tumour is localised (meaning it has not spread outside the prostate). 

25 March 2021

Unpacking after the trip

For the first time, this Ar Event was available solely online, but that didn’t stop viewers from interacting on all of the available platforms - Zoom, Facebook Live and YouTube - with more than 200 questions shared with our panel of experts.  According to Dr. Bill Richards (who you’ll get to know later!), we are “Moving into new terrain… and we welcome you to join us!”

24 March 2021

The Neuronautas Are Back!

This Gulbenkian Knowledge Academy is looking for young people ready to embark on an intergalactic journey into the future of neuroscience!

In this edition, candidates will be able to choose one of two possible trips - Long Flight (lasting about 4 weeks) or Short Flight (lasting around 2 weeks). For the first, 16 Neurocadets will be recruited and for the second, 8 Chimeras!

Subscribe to Champalimaud Research
Loading
Please wait...